Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

A legfontosabb adatok

Hol
Alexandria, Boca Raton, Boston, Chicago, Durham, Farmington Hills, Georgetown, Hershey, Kansas City, La Jolla, Los Angeles, Nashville, New York, Pittsburgh, Rochester, Spokane, Tampa és Washington D.C. (Egyesült Államok)Mind a 19 helyszín megnézése
Fázis
2. fázis

Helyszínek itt: Egyesült Államok

  • Integrated Neurology ServicesAlexandria, Egyesült ÁllamokNo longer taking part
  • Parkinson's Disease and Movement Disorder Center of Boca RatonBoca Raton, Egyesült ÁllamokNo longer taking part
  • Brigham and Women's HospitalBoston, Egyesült ÁllamokNo longer taking part
  • Rush University Medical Center-Allergy/ Immunology CenterChicago, Egyesült ÁllamokNo longer taking part
  • Duke University School of Medicine - Duke Neurological Disorders Clinic - Morreene Road LocationDurham, Egyesült ÁllamokNo longer taking part
  • Detroit Clinical Research Center, PCFarmington Hills, Egyesült ÁllamokNo longer taking part
  • Texas Movement Disorder SpecialistsGeorgetown, Egyesült ÁllamokNo longer taking part
  • Penn State Milton S. Hershey Medical CenterHershey, Egyesült ÁllamokNo longer taking part
  • University of Kansas Medical CenterKansas City, Egyesült ÁllamokNo longer taking part
  • University of California San DiegoLa Jolla, Egyesült ÁllamokNo longer taking part
  • University California Los Angeles Medical Center (Ucla)Los Angeles, Egyesült ÁllamokNo longer taking part
  • Vanderbilt University Medical Center (VUMC)Nashville, Egyesült ÁllamokNo longer taking part
  • Columbia University Medical Center The Neurological Institute of New YorkNew York, Egyesült ÁllamokNo longer taking part
  • NYU Medical Center - Dysautonomia centerNew York, Egyesült ÁllamokNo longer taking part
  • University of PittsburghPittsburgh, Egyesült ÁllamokNo longer taking part
  • Mayo ClinicRochester, Egyesült ÁllamokNo longer taking part
  • Inland Northwest ResearchSpokane, Egyesült ÁllamokNo longer taking part
  • University of South Florida Parkinson's Disease and Movement Disorders CenterTampa, Egyesült ÁllamokNo longer taking part
  • MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)Washington D.C., Egyesült ÁllamokNo longer taking part

A vizsgálat adatai

Ki végzi
Teva Branded Pharmaceutical Products R&D LLC
Azonosító
NCT06568237EU 2023-505320-54-00
A regiszteradat frissítve
2026. november 5.
Eredeti leírás
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).A teljes eredeti leírásKevesebb

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)

The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).

A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286.

Another secondary objective is to evaluate the safety and tolerability of TEV-56286.

The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.

Bevonási feltételek: is considered to be "clinically possible" or "clinically probable" MSA as determined by the Gilman criteria; is medically and psychiatrically stable, as indicated by medical and psychiatric history, as well as physical and neurological examination; Females of child bearing potential (CBP) may be included only if they have a negative pregnancy test at the screening and baseline visits; Females of CBP whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods; Males who are potentially fertile/reproductively competent (not surgically [eg, vasectomy] or congenitally sterile) and their female partners who are of CBP must use, together with their female partners, highly effective birth control methods; Additional criteria apply; please contact the investigator for more information.

Kizáró feltételek: has participated in another clinical study involving administration of an IMP within 3 months or 5 half-lives (whichever is longer) of this IMP prior to screening; has a history of, or acknowledges, alcohol or other substance abuse in the 12 months before screening; participant is using or consuming any prohibited concomitant medications within the specified exclusionary windows of this study; Additional criteria apply; please contact the investigator for more information; has 2 or more relatives with history of MSA, suggestive of an alternative diagnosis other than MSA; has a known hypersensitivity to any components of the IMP; is a female participant who is pregnant or breastfeeding, or plans to become pregnant during the study; is of a vulnerable population (eg, people kept in detention or jail).

ClinicalTrials.gov NCT06568237 · EU CTIS 2023-505320-54-00